“The registration of the vaccine is expected on February 20, 2021,” the website said.

Phase 2 research is expected to finish at the beginning of 2021.

“After that, a mass trial of the drug with 3,000 volunteers is planned,” the website said.

Russian Security Council Deputy Chairman Dmitry Medvedev said earlier this month that the vaccine developed by the Chumakov research institute is the most classic drug as it contains an inactive virus of atypical COVID-19 pneumonia and this vaccine “works on the same principles as vaccines have been working for 200 years”.